Navigation Links
Shelved bowel-syndrome drug still in demand

After receiving thousands of letters from desperate patients, the FDA will convene a panel of outside experts to discuss whether Lotronex, an irritable bowel syndrome(IBS) medication,// can come back on the market. To meet demand, FDA official Victor Raczkowski says, his agency has expanded time allowed for public testimony at the advisory committee meeting.

IBS, affecting up to 15% of Americans, causes symptoms including lower abdominal pain, a sudden need to have a bowel movement, diarrhoea and constipation. Lotronex was the first new IBS treatment in years and the only one approved for women who mainly have diarrhoea, roughly one-sixth of all IBS patients. Glaxo Wellcome, now GlaxoSmithKline, pulled Lotronex in December 2000, 8 1/2 months after the drug's debut. About 300,000 patients had taken it, according to Glaxo.

In June 2000, the FDA began receiving reports of Lotronex users suffering severe constipation and ischemic colitis, or inflammation of the large bowel, caused by reduced blood flow. By year's end, the FDA had learned of 141 such cases, including 7 deaths, according to the Public Citizen Health Research Group, which had petitioned the agency in September 2000 to withdraw the drug. Glaxo and FDA officials have been meeting regularly since January 2001 to discuss ways of limiting adverse effects.

Page: 1

Related medicine news :

1. Women with borderline ovarian tumors can still preserve their fertility
2. Drugs Banned worldwide still available in India
3. Antidepressants still being prescribed to Teenagers despite being banned!
4. Tinnitus: a problem which is still ambiguous
5. Anti-depressants may cause stillbirth
6. Chernobyl Disaster still Causing Cancer
7. Free Access to Taxotere Instills New Hope among Early Stage Breast Cancer Patients
8. Post-tsunami trauma still haunts children
9. Wet Distillers Grains Could Play a Role in Cattle Diets
10. "Make AIDS Therapy affordable" - Physicians demand
11. SARS: Indias drugs in demand
Post Your Comments:

(Date:11/25/2015)... ... November 25, 2015 , ... ... seniors, is resulting in a way for homeless people to have a more ... launched a new initiative whereby they are repurposing plastic bags into sleeping mats ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Many people ... fatigue, fuzzy-headedness, weight gain, cold hands, and dry skin. But many people who find ... diet and exercise regimen instead of their thyroid, especially if they don’t have any ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a non-profit ... as well as raising public awareness of the disorder while helping to bring ... donation of $35,000 to bolster progress at the Tuberous Sclerosis Complex Center at ...
(Date:11/25/2015)... ... 25, 2015 , ... Since its launch in 2012, the ... stem cell therapies to patients with chronic degenerative medical conditions. Now, the U.S. ... Trademark (RTM). , Organizations are required to hold a registered trademark in order ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to be thankful ... Create Real Impact awards. California Casualty is proud to support the contest ... distracted and reckless driving, the number one killer of young drivers. , Almost ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 25, 2015 Asia ... which BioLight and the New Investors will make a ... via a private placement. The financing will help IOPtima ... system used in the treatment of glaucoma, as well ... the IOPtimate™ system with the U.S. Food and Drug ...
(Date:11/25/2015)... 25, 2015  Mindray Medical International ... MR ), a leading developer, manufacturer ... today announced that it will hold ... shareholders at the Company,s Hong Kong office (FLAT/RM ... Edward West Road, Mongkok KL, Hong Kong) ...
(Date:11/25/2015)... Developmental, commercial, and regulatory/legal strategies ... of pharmaceutical products, says GBI Research ... strategies all play a key role in boosting the ... . --> Developmental, commercial, ... boosting the profitability of pharmaceutical products, says GBI ...
Breaking Medicine Technology: